



Ref: FOIA Reference 2023/24-438

Date: 29th October 2023

Email foi@uhnm.nhs.uk

Dear

I am writing to acknowledge receipt of your email dated 6th October 2023 requesting information under the Freedom of Information Act (2000) regarding lung cancer

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 I am analysing the treatment of lung cancer and would greatly appreciate if you could answer the following questions:

How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- **ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)**
- **Amivantamab**
- **Atezolizumab Monotherapy**
- **Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel**
- **Dabrafenib + Trametinib**
- **Docetaxel monotherapy or in combination with Carboplatin/Cisplatin**
- **Durvalumab**
- **Gemcitabine**
- **Nitedanib + Docetaxel**
- **Nivolumab**
- **Osimertinib**
- **Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)**
- **Paclitaxel**
- **Pembrolizumab Monotherapy**
- **Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)**
- **Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)**
- **Pemetrexed + Platinum (Carboplatin/Cisplatin)**
- **RET Inhibitors (Pralsetinib, Selpercatinib)**

- Sotorasib
- Tepotinib
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
- Other active systemic anti-cancer therapy
- Palliative care only

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5 *This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.* See below:

- ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) - 8
- Amivantamab - 0
- Atezolizumab Monotherapy - <5
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel - 0
- Dabrafenib + Trametinib - 0
- Docetaxel monotherapy or in combination with Carboplatin/Cisplatin - <5
- Durvalumab - <5
- Gemcitabine - 0
- Nitedanib + Docetaxel - 0
- Nivolumab - 0
- Osimertinib - 13
- Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) - <5
- Paclitaxel - 11
- Pembrolizumab Monotherapy - 18
- Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) - 9
- Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) - 20
- Pemetrexed + Platinum (Carboplatin/Cisplatin) - 15
- RET Inhibitors (Pralsetinib, Selpercatinib) - <5
- Sotorasib - <5
- Tepotinib - 0
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin - 13
- Other active systemic anti-cancer therapy - <5• Palliative care only - data not held for patients on Best Supportive Care, as not on active SACT (Systemic Anti-Cancer Therapy)

Q2 Does your Trust/health board participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each active trial and the number of patients taking part.

A2 See below:

Project Short title	Project site status	Recruited
CANC - 3370: ATLANTIC - MEDI4736 in locally advanced or metastatic NSCLC previously received >2 syst	Closed to recruitment - in follow up	2
SARON	Closed to recruitment - in follow up	2
Adjuvant canakinumab vs placebo in stages II-IIIB resected NSCLC	Closed to recruitment - in follow up	3
Rad-IO	Open	1
PACIFIC-Real World	Closed to recruitment - in follow up	3
JDQ443B12301	Open	0

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

Yours,



University Hospitals
of North Midlands
NHS Trust

Rachel Montinaro
Data Security and Protection Manager - Records

